- Provides Non-mail Options for Proxy Voting -
SAN DIEGO AND VANCOUVER, June 6, 2011 /CNW/ - Protox Therapeutics Inc.
(the "Company" or "Protox") (TSX: PRX), a leader in the development of
receptor targeted therapeutic fusion proteins, today announced that its
2011 Annual General Meeting of the Shareholders will be held on
Thursday, June 9, 2011 at 9:00 a.m. PT at the offices of Fasken
Martineau at 2900 - 550 Burrard Street in Vancouver, British Columbia.
Due to the ongoing negotiations and potential for full scale strike
between Canada Post and the Canadian Union of Postal Workers,
shareholders should also be aware of non-mail voting options. Proxy forms also permit 24 hour a day voting by telephone and internet.
To vote by telephone or the Internet, you will need to provide your
CONTROL NUMBER listed on your proxy form.
To vote by phone, dial toll free from a touch tone phone: 1-866-732-VOTE
To vote on the internet, go to www.investorvote.com.
If you vote by telephone or the Internet, DO NOT mail back your proxy
Voting by mail may be the only method for securities held in the name of
a corporation or securities being voted on behalf of another
Voting by mail or by Internet are the only methods by which a holder may
appoint a person as proxy holder other than the Management nominees
named on the proxy form.
Protox Therapeutics is a leader in advancing novel, receptor targeted
therapeutic fusion proteins. Two drug candidates derived from the
company's INxin™ and PORxin™ platforms are in clinical development.
Protox's lead program, PRX302 (PORxin), achieved positive results from
its Phase 2b placebo controlled trial called TRIUMPH, to treat benign
prostatic hyperplasia (BPH or enlarged prostate). Protox has partnered
with Kissei Pharmaceuticals for the development and commercialization
of PRX302 in Japan. PRX321 (INxin) is being developed for the treatment
of various cancers and has received Fast Track Designation and Orphan
Drug Status from the US FDA and EMEA for the treatment of primary brain
cancer. For more information, please visit www.protoxtherapuetics.com.
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements, and therefore these statements should not
be read as guarantees of future performance or results. All
forward-looking statements are based on Protox' current beliefs as well
as assumptions made by and information currently available to Protox
and relate to, among other things, anticipated financial performance,
business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by Protox in its
public securities filings; actual events may differ materially from
current expectations. Protox disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
SOURCE Protox Therapeutics Inc.
For further information: